DxDiscovery

DxDiscovery is a biotechnology research and development firm that focuses on creating high-affinity antibodies to microbial antigens for use in rapid, point-of-care (POC) diagnostics and potential therapeutics for infectious diseases. The company identifies specific microbial biomarkers associated with infections and develops monoclonal or polyclonal antibodies to detect them. These antibodies are integrated into optimized, immunoassay-based diagnostic platforms, with a primary emphasis on lateral flow immunoassay technology. By prioritizing diseases where current methods like culture or molecular approaches are slow, expensive, or require specialized infrastructure, DxDiscovery aims to provide diagnostic solutions that offer fast turnaround times and minimal operational requirements.

The company's work is critical for improving patient care by enabling earlier, more accurate diagnoses, which facilitate more effective treatment and proactive screening before symptoms worsen. Founded in 2012 as a spinoff from the University of Nevada, Reno, DxDiscovery leverages partnerships with clinical laboratories, universities, and healthcare sites to advance its research. The firm is supported by competitive grants from the National Institutes of Health (NIH) and the Department of Defense. Its business model involves licensing detection reagents and biomarkers to partner companies for large-scale manufacturing, while also working toward internal production capabilities for select diagnostic products.